Inflammatory arthritis affects millions of people worldwide, keeping many of them from living life fully even when their condition is under control. While modern treatments help over 80% of patients reach low disease activity, daily struggles like pain and fatigue often remain. A new online program
Jayden James wasn’t supposed to be throwing opponents down on a mat in Kentucky this week. He was supposed to be cramming for a finance test at his New Jersey high school. But instead of worrying about spreadsheets, he spent Thursday outgrabbing seasoned college wrestlers twice his age in the U. S.
ALS is a rare but cruel disease that slowly shuts down the body while leaving the mind intact. Doctors have only approved three drugs for it since the mid-1990s, and none of them cure or stop the disease—they merely slow it down a little. Part of the problem is money. Running trials for ALS is extre
Japan started using DNA tests in court cases back in 1989, the first year such science was allowed as evidence. Researchers looked at every criminal case in a major legal database from that year up until 2024, focusing on how often DNA was accepted, how many people were found guilty, and what senten
In Canada, researchers often submit applications to ethics boards before starting a study. These forms normally ask for basic details about the trial, but they rarely prompt investigators to think about who will benefit from the research or how patients will be involved in decisions. The study lo
Doctors in the U. S. now have another tool to fight a tough cancer. The FDA gave the green light for early use of an experimental pill called daraxonrasib. It targets pancreatic ductal adenocarcinoma, a fast-spreading form of pancreatic cancer that has already resisted other treatments. Patients who
Research on semaglutide, a once-a-week shot, shows it can help people lose noticeable weight—up to one-sixth of their body weight in some cases. Trials called STEP 1, 3, and 4 focused on adults without diabetes and found weight drops between ten and seventeen percent. For those with type 2 diabetes
For decades, drug testing followed the same slow rhythm. Researchers ran trials in stages, then paused for months to analyze data before asking regulators for the next step. Patients waited years for treatments while paperwork piled up. Now, a new FDA approach cuts out the waiting by letting regulat
Quick action saves lives when someone has a heart attack. That’s why some emergency teams now give aspirin on the spot. But does this practice hold up under real-world conditions? A study called CELEBRATE looked at whether early aspirin use actually helps patients before they even get to the hospita
A French biotech company just got a two-year break from paying back millions in loans, giving it more cash to push forward on cutting-edge research. The firm, known for developing treatments targeting tough diseases, reached a deal with lenders to delay loan payments totaling around €17. 8 million.
